SUBSCRIBE
SUBSCRIBE
Tristan Manalac

Tristan Manalac

Contributing Writer | News

Tristan is an independent science writer based in Metro Manila, with more than eight years of experience writing about medicine, biotech and science. Being formally trained in molecular biology, he once dreamed of collecting degrees and starting his own lab. But these days, he finds his greatest joy in a bottle of beer and a beautiful sentence. He can be reached at tristan.manalac@biospace.com, tristan@tristanmanalac.com or on LinkedIn.

Senior lady massaging hand suffering from rheumatoid arthritis concept, old adult female patient touching wrist feeling hurt joint pain having osteoarthritis disease health problem, close up view
5 Lupus Patients in Remission Following CAR T Cell Therapy
Five patients with systemic lupus erythematosus (SLE) are in remission after receiving CAR T cell therapy, according to a recent study.
September 16, 2022
 · 
2 min read
 · 
Tristan Manalac
Harold Cunningham/Getty Images
Policy
Swiss Agency Probes Novartis over Potential Unlawful Patent Use
Novartis confirmed it is the subject of an investigation by the Swiss Competition Commission over possible unlawful patent use.
September 15, 2022
 · 
2 min read
 · 
Tristan Manalac
Genetown
ICER Deems Hemophilia Gene Therapies Worth the $2.5M Price Tag (Updated)
The Institute for Clinical and Economic Review (ICER) concluded that even at a hefty lifetime cost of $2.5 million, gene therapies for hemophilia A and B are worth it.
September 15, 2022
 · 
3 min read
 · 
Tristan Manalac
male hands with wrist watch is considered American dollars. Hands holding dollar cash. 1000 dollars in 100 bills in a man's hand close-up on a dark background. hundred
Business
Money on the Move: Sparing Vision, RayzeBio, Nimbus and More Garner Funds
This week was rife with Series financings, which channeled money into innovative treatments for immune diseases and cancers, genomic treatments and precision healthcare.
September 14, 2022
 · 
5 min read
 · 
Tristan Manalac
Adding samples to a 96 well plate using a multi-channel pipettor in a biosafety cabinet.
Business
Capstan Therapeutics Launches with $165M for Precise in Vivo Cell Engineering
With $165 million in the bank, Capstan launched Wednesday to combine the potency of cell therapy with the precision of genetic medicines against various difficult-to-treat diseases.
September 14, 2022
 · 
2 min read
 · 
Tristan Manalac
Harold Cunningham/Getty Images
Policy
Court Dismisses Whistleblower Lawsuit Against Novartis
A Manhattan court dismissed a whistleblower lawsuit against Novartis, which had alleged the company paid doctors to promote its multiple sclerosis drug Gilenya.
September 14, 2022
 · 
2 min read
 · 
Tristan Manalac
Business
Pretzel Therapeutics Launches with $72M to Advance Mitochondrial Therapies
Pretzel Therapeutics launched Monday with $72.5 million in Series A financing to develop novel, mitochondria-based therapies to treat rare genetic disorders and diseases of aging.
September 12, 2022
 · 
3 min read
 · 
Tristan Manalac
Jeremy Moeller/Getty Images
FDA
BMS Wins Landmark Approval in Plaque Psoriasis, Avoids Black Box Label
BMS announced that the FDA approved Sotyktu for adults with moderate-to-severe plaque psoriasis, marking this indication’s first oral treatment innovation in nearly a decade.
September 12, 2022
 · 
3 min read
 · 
Tristan Manalac
Chesnot/Getty Images
Business
Phase III Data in Hand, Sanofi-Regeneron’s Dupixent Targets Another Approval
Sanofi and Regeneron presented results from the Phase III PRIME trial that showed Dupixent strongly improves itching and skin lesions in adult patients with prurigo nodularis.
September 9, 2022
 · 
2 min read
 · 
Tristan Manalac
Alnylam CEO Yvonne Greenstreet_Alnylam Pharmaceuti
Drug Development
Alnylam’s Patisiran Clears Phase III Hurdle in ATTR With Cardiomyopathy
Alnylam announced results Thursday from the APOLLO-B study of patisiran that showed improved functional capacity in (ATTR) amyloidosis patients with cardiomyopathy.
September 8, 2022
 · 
2 min read
 · 
Tristan Manalac
Pictured: Financing concept/Getty Images
Business
SpringWorks Scores GSK Partnership Expansion, $225M Raise
SpringWorks announced the expansion of its partnership with GlaxoSmithKline to develop nirogacestat in combination with GSK’s Blenrep for relapsed or refractory multiple myeloma.
September 8, 2022
 · 
2 min read
 · 
Tristan Manalac
Andrea Izzotti/Shutterstock
Business
FDA Job Cuts Loom with Partisan Lock in Congress - Updated
Thousands of FDA employees may lose their jobs if Congress doesn’t reappropriate funding currently in place by the end of the month.
September 7, 2022
 · 
3 min read
 · 
Tristan Manalac
Business
Money on the Move: Arcutis Acquires Ducentis and a Hefty Gift to UCSD (Updated)
Arcutis scoops up Ducentis and its lead asset DS-234, UC San Diego receives $150M earmarked for stem cell, regenerative medicine research and Arsenal and ILiAD reel in new funds.
September 7, 2022
 · 
3 min read
 · 
Tristan Manalac
Business
Ionis, AstraZeneca Report Promising Late-Stage Data for ATTR Antisense Candidate
Preliminary findings from the NEURO-TTRansform trial show Ionis’ and AstraZeneca’s eplontersen is potentially a safe and effective treatment for patients with amyloidosis.
September 7, 2022
 · 
3 min read
 · 
Tristan Manalac
Jonathan Weiss/Shutterstock
Drug Development
FDA Okays Imfinzi as First Immunotherapy for Advanced Biliary Tract Cancer
The FDA approved AstraZeneca’s Imfinzi plus with gemcitabine-cisplatin chemotherapy as the first immunotherapy for adult patients with locally advanced or metastatic biliary tract cancer.
September 6, 2022
 · 
2 min read
 · 
Tristan Manalac
Load More